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Abstract
Purpose We hypothesized that assessment of myocardial
sympathetic activity with no-carrier-added (nca)
123I-meta-
iodobenzylguanidine (MIBG) compared to carrier-added (ca)
123I-MIBG would lead to an improvement of clinical per-
formance without major differences in radiation dosimetry.
Methods In nine healthy volunteers, 15 min and 4 h planar
thoracic scintigrams and conjugate whole-body scans were
performed up to 48 h following intravenous injection of
185 MBq
123I-MIBG. The subjects were given both nca
and ca
123I-MIBG. Early heart/mediastinal ratios (H/M),
late H/M ratios and myocardial washout were calculated.
Thefraction ofadministeredactivityintensourceorganswas
quantified from the attenuation-corrected geometric mean
counts in conjugate views. Radiation-absorbed doses were
estimated with OLINDA/EXM software.
Results BothearlyandlateH/Mwerehigherfornca
123I-MIBG
(ca
123I-MIBG early H/M 2.46±0.15 vs nca
123I-MIBG
2.84±0.15, p=0.001 and ca
123I-MIBG late H/M 2.69±
0.14 vs nca
123I-MIBG 3.34±0.18, p=0.002). Myocardial
washout showed a longer retention time for nca
123I-MIBG
(p<0.001). The effective dose equivalent (adult male model)
for nca
123I-MIBG was similar to that for ca
123I-MIBG
(0.025±0.002mSv/MBqvs0.026±0.002mSv/MBq, p=0.055,
respectively).
Conclusion No-carrier-added
123I-MIBG yields a higher
relative myocardial uptake and is associated with a higher
myocardialretention.Thisdifferencebetweennca
123I-MIBG
and ca
123I-MIBG in myocardial uptake did not result in
major differences in estimated absorbed doses. Therefore,
nca
123I-MIBG is to be preferred over ca
123I-MIBG for the
assessment of cardiac sympathetic activity.
Keywords Cardiology.Heartfailure.Sympathetic
innervation. 123I-MIBG.Dosimetry
Introduction
Meta-iodobenzylguanidine (MIBG), in analogy to catechol-
amines, is removed primarily from the circulation by sodium-
driven, desipramine-sensitive, high-affinity transporters into
the presynaptic noradrenergic neurons and stored in the
presynaptic storage vesicles (called uptake 1) [1]. In addition,
there is MIBG uptake by the corticosterone-sensitive, low-
affinity, high-capacity, extra-neuronal transport system,
originally named uptake 2 [2]. Uptake 1 predominates at
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as uptake 2 predominates at higher concentrations [3].
Blockingexperimentshaveshownthatuptake2isresponsible
for up to 61% of myocardial MIBG uptake [4–8]. For routine
clinical studies, the production of
123I-MIBG involves iso-
topic exchange that gives a low specific activity (presence of
aconsiderableamountofcarrier,i.e.,nonradio-labeledMIBG,
in the final product) [9]. As uptake 2 predominates at higher
concentration of MIBG, scintigraphic-determined semi-
quantitative parameters will not improve by increasing the
dose of
123I-MIBG using a relatively low-specific-activity
123I-MIBG compound. Increasing the dose of relatively low-
specific-activity
123I-MIBG might even lead to saturation of
the uptake-1 mechanism. Reduction of the total amount of
MIBG in combination with a higher specific activity (higher
ratio radio-labeled/nonradio-labeled, i.e., no-carrier-added
(nca)
123I-MIBG), however, may favor myocardial uptake
of
123I-MIBG through uptake 1 [10]. In a blocking exper-
iment (animal setting), we have shown that nca
123I-MIBG
leads to a better contrast between specific and nonspecific
123I-MIBG uptake as compared to carrier-added (ca)
123I-
MIBG [11].
We hypothesized that the experimental differences in
myocardial uptake of nca
123I-MIBG compared to ca
123I-
MIBG observed in the animal studies should also be found
in human subjects. This increase in myocardial uptake would
lead to an improvement in the clinically relevant semi-
quantitativeparametersofmyocardial
123I-MIBG uptake [i.e.,
early heart/mediastinal ratios (H/M), late H/M ratios and
myocardial washout]. In addition, we hypothesized that this
improved myocardial uptake of nca
123I-MIBG would not
lead to any major differences in dosimetry. In the present
study, we evaluated the intra-individual differences of clin-
ical performance and radiation dosimetry for both nca
123I-
MIBG and ca
123I-MIBG.
Materials and methods
Study protocol
Healthy volunteers were injected with approximately
185 MBq of ca
123I-MIBG and with approximately
185 MBq of nca
123I-MIBG on two separate days with a
2-week interval. To minimize the possibility of order bias,
five of the subjects received first ca
123I-MIBG followed by
nca
123I-MIBG, and in the other four subjects, the order was
reversed. After injection, images were obtained for the
assessment of clinically relevant parameters of MIBG and
also for calculation of radiation dosimetry. The study
protocol was approved by the institutional Medical Ethics
Committee.
Study group
Nine healthy volunteers (four women and five men), with a
mean age of 29 years (range 21–59 years) and a low
likelihood of coronary artery disease (<5%), were included
after they had given their written informed consent. The
subjects were free of disease based on screening by medical
history and physical examination. None of the subjects used
any medication that could interfere with
123I-MIBG uptake.
Each subject received approximately 200 mg potassium
iodide (10% solution) orally, taken as three daily fraction-
ated doses on the day before and on the day of injection, to
block thyroid uptake of free radioactive iodide.
Radiopharmaceuticals
No-carrier-added
123I-MIBG was produced via the well-
established Cu(I)-catalyzed nonisotopic (
123I/Br) exchange
reaction in an acidic, aqueous medium [12]. A reproducible
and high labeling yield (70–80%, approximately 5–6 GBq
nca
123I, at the time of synthesis; Na
123I from Mallinckrodt
Medical, Tyco Healthcare BV, Petten, The Netherlands)
was obtained, and final reaction mixture was injected into a
semi-preparative high-performance liquid chromatography
(HPLC) system (using an isotonic EtOH/acetate eluent) to
separate the radio-iodinated
123I-MIBG from its brominated
precursor. A second HPLC separation was performed on
the first collected fraction to obtain nca
123I-MIBG, free
from pseudo-carrier (bromo-precursor). The ultimate col-
lected nca
123I-MIBG was further diluted with an isotonic
citrate buffer (pH 5), filtrated, dispensed and sterilized by
autoclavation. The radiochemical purity of the autoclaved
nca
123I-MIBG was higher than 98% (30 h after synthesis),
with an overall yield of 55–65%. Postproduction UV-HPLC
analyses of the final product showed complete absence of
bromo-precursor. No-carrier-added
123I-MIBG had a specific
activity in the order of 1,700 GBq/μmol MIBG.
Carrier-added
123I-MIBG was produced according to an
isotopic exchange procedure and had a radiochemical purity
of more than 97% and a specific activity in the order of
40 MBq/μmol MIBG. By comparison, the difference in
specific activity between nca
123I-MIBG and ca
123I-MIBG
was more than a factor of 10.000. The specific radioactivity
of ca
123I-MIBG can therefore be considered to be low but
is that encountered in current routine clinical practice.
Instrumentation
All images were obtained with a dual-head scintillation
camera (E.cam, Siemens, Germany) fitted with medium
energy collimators. A 15% energy window was used for
123I and
57Co. The medium energy collimators provided
minimum septum penetration of the higher energy photons
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123I radionuclide [13]. All whole-body scans, both
emission and transmission, were obtained in anterior and
posterior views with a scan speed of 8 cm/min. All
measurements were obtained in each subject for both ca
123I-MIBG and nca
123I-MIBG. The same radionuclide
dose calibrator was used for all
123I activity measurements.
Semi-quantitative
123I-MIBG myocardial indices
At 15 min and 4 h post-injection of
123I-MIBG, 10 min
anterior planar acquisitions were made of the thorax.
Images were made with a 256×256 matrix size, using the
settings described above.
Whole-body emission scans
For each subject, a series of six whole-body emission scans
were obtained at 30 min, 1.5, 2.5, 4.5, 6 and 24 h post-
injection of
123I-MIBG. In two subjects, whole-body scans
were also obtained at 48 h. The stability of these measure-
ments over the total measurement period was monitored by
including a vial containing 2 MBq of
123I placed between
the lower legs of the subject during each emission scan.
A quality control check of the equality of the sensitivity
of anterior and posterior collimated detectors for
123I was
verified, according to the NEMA NU-1 protocol [14]. The
calibration factor applied to convert whole-body counts to
MBq was measured and monitored for the anterior detector
head. This calibration factor gave the conversion of counts
to MBq measured in air, without absorption of the imaging
pallet. Because of interference of the imaging pallet, a
similar measurement in air for the posterior detector head
was not possible. This factor was obtained from a whole-
body scan of the Petri dish, containing an amount of
123I
(25 MBq) exactly calibrated in the radionuclide dose
calibrator, placed on the imaging table. The net counts were
obtained from a circular region of interest (ROI) over the
Petri dish image and a copy of the circular ROI placed in a
background region. The activity was calibrated to the actual
time of scanning over the Petri dish.
Whole-body transmission imaging
Forthe purpose ofattenuation correction,a dual-head whole-
body transmission scan was obtained for each subject before
123I MIBG injection. A 300 MBq
57Co flood source was
placed on the lower detector head. The upper detector head
thus measured transmission through the patient and imaging
table in anterior view, whereas the lower detector measured
counts in air. In the dosimetry calculations, a correction was
made for the difference in attenuation between
57Co and
123I
using a measured linear broad-beam attenuation factor of
0.145 cm
−15 7 Co and 0.138 cm
−1 for
123I.
Blood and urine
Blood samples were obtained at 10 min, 1 h and sub-
sequently directly before each whole-body scan. Three
duplicate 1 ml samples of blood were measured in a gamma
sample changer with an appropriate standard
123I activity to
convert from counts to MBq. Total amount of radioactivity
in the blood was calculated using a total blood volume
based on gender and individual body weight and height and
expressed as % injected dose of
123I-MIBG [15–17].
Urine was collected to verify excretion kinetics. The urine
was collected in separate containers corresponding to
separate collection periods. The first collection periodstarted
directly after injection of
123I-MIBG and was completed
after the first whole-body scan. The subsequent collection
periods ended before each successive whole-body scan.
This gave five containers up to 24 h and six containers up
to 48 h. The urine volume in each container was determined
by the net weight of each urine container. Three duplicate
1 ml samples from each container were measured in the
gamma sample changer and the total urine activity estimated
using the total urine volume from each collection period.
Image analysis—semi-quantitative
123I-MIBG myocardial
indices
An experienced nuclear medicine technologist (AvM), blind
to the radiopharmaceutical used, processed all planar images
(HERMES workstation, Nuclear Diagnostics, Stockholm,
Sweden).AROIformyocardialactivitywasmanuallydrawn
andincludedbothventriclesandatrialactivity,ifobserved.A
fixed rectangular mediastinal ROI (100 pixels) was drawn in
the upper mediastinum, using the apices of the lungs as
anatomic landmarks (Fig. 1). The H/M (early and late) was
calculated as the ratio of the counts/pixel in the two ROIs.
Myocardial washout was calculated as:
earlyH=M   lateH=M ðÞ
earlyH=M

  100%
and myocardial retention was calculated as:
earlyH   lateHdc
earlyH

  100%
where late H
dc stands for late H decay corrected. The cal-
culation of myocardial retention implies that the lower the
outcome (i.e., lesser myocardial washout), the higher the
myocardial retention.
Image analysis—whole-body scans
For each subject, an anterior and posterior set of ROIs was
created for the activity observed in the source organs of
800 Eur J Nucl Med Mol Imaging (2008) 35:798–807interest: liver, myocardium, lungs, kidneys, spleen, thyroid,
bladder, submandibular and parotid glands, intestines and
over the total body. The anterior lung ROI was obtained
from the anterior
57Co transmission scan. Different back-
ground (BG) ROIs were also obtained and applied to the
various organ ROIs: groin (BG correction for liver, kidneys,
bladder, spleen, intestines), mediastinum (BG correction for
myocardium), thigh (BG correction for thyroid), head (BG
correctionforsubmandibularandparotidglands)andoutside
the body ROI (BG correction for whole-body ROI). The
anterior and posterior ROIs mirrored each other. Once a set
of anterior and posterior ROIs had been created, this set was
applied to each whole-body scan of the ca
123I MIBG and
nca
123I MIBG studies, including the transmission scans.
Adjustment was applied when necessary for a difference in
position of the patient. The counts and pixels in each ROI
were obtained (HERMES Medical Solutions, Stockholm,
Sweden).
For each emission whole-body scan, organ counts were
corrected for their appropriate BG counts. The
57Co
attenuation correction factor for each organ was obtained
from the square root of the ratio (anterior counts per pixel/
posterior counts per pixel) in the transmission scan. This
57Co attenuation factor was then corrected to
123I attenuation
using the measured broad beam linear attenuation factors.
The attenuated corrected counts were ultimately converted
to MBq and percentage of injected activity. To obtain
biological kinetics, a decay correction was applied, using the
time between injected activity and start of the whole-body
scan, plus an extra 10 min, as the decay time interval.
Dosimetry
The OLINDA/EXM software was used to obtain absorbed
doses [18]. This software includes a kinetic input module
for determining organ residence times. The residence times
forthesourceorganswereobtainedusingtheOLINDA/EXM
kinetic input model, applying a two- or three-exponential fit
to the data of each source organ. The whole-body retention
data,wherebythegeometric mean counts inthefirstscan was
set equal to 100% of injected activity, corresponded with the
accumulated activity excreted in the urine. The whole-body
data were therefore used to calculate the total body residence
time and also formed the basis for the kinetics of the urinary
bladder contents. The blood activity was input into the re-
mainder body organ of OLINDA/EXM. The difference
between the total number of disintegrations in total body
and in the sum of all source organs, excluding the urinary
bladder contents, was appliedtothemuscleasa sourceorgan.
The number of disintegrations in urinary bladder contents
was calculated based on the whole-body excretion (two-
exponential component fit) and assuming a 4-h bladder
voiding interval. The self-dose to the salivary glands was
estimated using the OLINDA/EXM sphere model. The
OLINDA/EXM software estimates intestinal absorbed dose
onlyonthe basisofintra-luminalactivityanddoes notcorrect
for intestine self-dose. However the intestine is a sympathet-
ically innervated organ [19, 20]. A subsequent correction
was made to the beta-component of the absorbed dose
estimate for the intestinal wall. The radiation dose estimates
were calculated for each subject independently and then
averaged. Separate sets of values were generated for the
OLINDA/EXM adult male and adult female input models.
All calculations were based on the assumption that the
product contained 100% pure
123I.
Statistical analysis
Normal distribution was assessed by the Kolmogorov–
Smirnov test. In the case of normal distribution, mean dif-
ferences were compared with a paired Student’s t test. In
the case of abnormal distribution, means were compared
with the Wilcoxon rank test (SPSS for Windows 11.5.1,
SPSS, Chicago, IL, USA). A p value <0.05 was considered
Fig. 1 Example of processing
procedure for early (a) and late
(b) planar
123I-MIBG images.
The positioning of the mediasti-
nal ROI was standardized in
relation to the lung apex, the
lower boundary of the upper
mediastinum and the midline
between the lungs
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cated otherwise, data are expressed as mean±standard
deviation (SD).
Results
Semi-quantitative
123I-MIBG myocardial indices
Figure 2 shows the clinically relevant semi-quantitative
123I-MIBG indices. Both early and late H/M (Fig. 2a and b)
were higher for nca
123I-MIBG (early ca
123I-MIBG H/M=
2.46±0.15 vs nca
123I-MIBG=2.84±0.15, p=0.001; and
late ca
123I-MIBG H/M=2.69±0.14 vs nca
123I-MIBG=
3.34±0.18, p=0.002). The myocardial washout (Fig. 2c)
showed a trend towards a higher myocardial uptake over
time (negative myocardial washout) for nca
123I-MIBG (ca
123I-MIBG=−10.85±4.40% vs nca
123I-MIBG=−18.04±
4.31%). This trend, however, was statistically not signifi-
cant (p=0.128). In contrast, nca
123I-MIBG showed a
higher myocardial retention (Fig. 2d; i.e., lower myocardial
washout)of47%comparedtoca
123I-MIBG (ca
123I-MIBG=
23.07±2.29% vs nca
123I-MIBG=12.20±3.96%, p=0.003).
Dosimetry
Whole-body images of one subject, showing the biodis-
tribution of radioactivity after intravenous injection of
123I-
MIBG at different time points post-injection, are presented
in Fig. 3. The uptake pattern was already established at
30 min after injection, with definite uptake seen in the
myocardium, lungs, liver, intestines, submandibular and
parotid glands. Excretion to the urinary bladder was already
present by 30 min. No major changes in distribution over
time were observed up to 48 h after injection of
123I-MIBG.
Figure 4 shows the average time-activity curves obtained
for the myocardium, lungs, liver and total body. Although
the time activity curve of the myocardial wall for nca
123I-
MIBG was higher compared to that of ca
123I-MIBG
(statistically significant for all time points), there was no
difference in the washout rate between ca
123I-MIBG and
nca
123I-MIBG (Fig. 4a). The lungs and liver showed no
variation between ca
123I-MIBG and nca
123I-MIBG
(Fig. 4b and c). The total body showed a trend towards
slightly higher retention for nca
123I-MIBG compared to ca
123I-MIBG (Fig. 4d).
Table 1 gives the number of disintegrations (MBq-h/
MBq administered) for the different source organs. The
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Fig. 2 Comparison of clinical performance of ca
123I-MIBG vs nca
123I-MIBG. Early and late H/M were higher for nca
123I-MIBG (a and
b p=0.001 and p=0.002, respectively). Although myocardial retention
for nca
123I-MIBG (d) improved (p=0.003), the clinically used
myocardial washout showed no difference (c)
802 Eur J Nucl Med Mol Imaging (2008) 35:798–807Fig. 3 Anterior whole-body transmission (Trans) scan (obtained
before injection of
123I-MIBG) and anterior whole-body emission
images obtained from a 58-year-old male volunteer at several time
points after administration of ca
123I-MIBG (a) and of nca
123I-MIBG
(b). In this volunteer, the first voiding period after injection took place
after the second whole-body emission scan instead of the first whole-
body emission scan. A holder (seen on the transmission scan) for the
123I-standard (seen on the emission scans) was placed between the
lower legs of the volunteer(s)
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123I-
MIBG was higher than that for ca
123I-MIBG. Moreover,
nca
123I-MIBG showed higher numbers of disintegrations
for myocardium and muscle. The number of disintegrations
for urinary bladder contents was lower for nca
123I-MIBG,
indicating a slightly lesser excretion for nca
123I-MIBG.
The number of disintegrations for both ca
123I-MIBG as for
nca
123I-MIBG was highest for muscle, followed by liver
and urinary bladder contents.
Table 2 displays the averaged estimated absorbed doses
for the OLINDA/EXM adult male and female models for ca
123I-MIBG and nca
123I-MIBG The organs that received the
highest absorbed doses for both ca
123I-MIBG as for nca
123I-MIBG were the urinary bladder wall (based on a 4-h
voidinginterval),followed by thelowerlarge intestine,upper
large intestine, liver and myocardial wall (Table 2). Dose to
the myocardial wall was notably higher for the nca
123I-
MIBG, as would be expected based on the biokinetics. The
absorbed doses per organ for females were higher compared
to males for both ca
123I-MIBG as for nca
123I-MIBG. The
mean effective dose equivalent for the normal male adult for
ca
123I-MIBG was of the same order of magnitude as for nca
123I-MIBG (p=0.055). The mean effective dose equivalent
for the normal female adult for ca
123I-MIBG was slightly
lower compared to nca
123I-MIBG (p=0.026). The effective
dose equivalent and effective dose in females was, for both
ca
123I-MIBG and nca
123I-MIBG, higher compared to
males (p<0.001; Table 2).
Discussion
The main goal of this study was to test whether the
experimental differences, noted in animal studies, in myo-
cardial uptake of nca
123I-MIBG compared to ca
123I-MIBG
would also be seen in human subjects, without major
changes in dosimetry. Our findings indicate that, in general,
nca
123I-MIBG yields a higher relative myocardial uptake
compared to ca
123I-MIBG (25%). The difference between
nca
123I-MIBG and ca
123I-MIBG in myocardial uptake did
not result in major differences in estimated effective dose
equivalents or effective doses.
Semi-quantitative
123I-MIBG myocardial indices
The observed higher myocardial uptake of nca
123I-MIBG
as compared with ca
123I-MIBG in humans is in line with
previous studies. This difference was explained by a longer
myocardial retention time (i.e., negative myocardial wash-
out) for nca
123I-MIBG. Farahati et al. were the first to
report the use of nca
123I-MIBG for myocardial scintigra-
phy in humans. In a limited number of healthy volunteers
(n=3), planar-assessed nca
123I-MIBG showed an increase
in relative myocardial uptake compared with ca
123I-MIBG.
However, nca
123I-MIBG images were not superior to ca
123I-MIBG [21]. The authors related this lack in superiority
to in vivo deiodination, which resulted in higher background
activity. However, in patients with ventricular arrhythmias,
Samnick et al. [22] showed that the relative myocardial
uptake of nca
123I-MIBG as assessed with single-photon
emission computed tomography was higher than myocar-
dial uptake of ca
123I-MIBG. These findings were similar to
those reported in another cohort of patients evaluated for
tachyarrhythmia [23]. However, in none of these studies,
clinically relevant parameters of myocardial
123I-MIBG
uptake (i.e., early H/M, late H/M ratios and myocardial
washout) were reported. In addition, the study of Knickmeier
et al. [23] made a comparison between different patient
groups, and no direct comparison was made between nca
123I-MIBG and ca
123I-MIBG within the same patient.
Table 1 Number of disintegrations (MBq-h/MBq administered) for ca
123I-MIBG and nca
123I-MIBG for total body and each source organ
ca
123I-MIBG nca
123I-MIBG p value
Mean±SD Mean±SD
Total body 9.812±1.022 10.392±0.964 0.001
Salivary glands 0.122±0.025 0.123±0.035 0.964
Lower large intestine 0.442±0.070 0.440±0.062 0.881
Upper large intestine 0.442±0.070 0.440±0.062 0.881
Myocardial wall 0.290±0.051 0.360±0.083 0.017
Kidneys 0.248±0.071 0.259±0.078 0.504
Liver 2.330±0.516 2.433±0.410 0.236
Lungs 0.616±0.127 0.621±0.129 0.853
Muscle 5.000±0.881 5.424±0.890 0.010
Spleen 0.089±0.030 0.090±0.041 0.915
Thyroid 0.035±0.008 0.044±0.020 0.108
Urinary Bladder Contents 1.130±0.147 1.079±0.141 0.019
Remainder 0.196±0.033 0.182±0.033 0.054
The p values are obtained from paired individual results.
804 Eur J Nucl Med Mol Imaging (2008) 35:798–807Therefore, differences between nca
123I-MIBG and ca
123I-
MIBG myocardial uptake may have been blunted by
regression to the mean. Although Faharati et al. reported
on dosimetry of nca
123I-MIBG, data on radiation-absorbed
dose estimates were only obtained in one healthy subject.
The negative myocardial washout (Fig. 4c) is indicative
of a higher myocardial uptake over time (Fig. 4d). This
finding is in line with previous studies in healthy volunteers
[24] and is probably an indication of a low myocardial
sympathetic activity. In addition, the negative myocardial
washout may (to some extent) be explained by a slower
myocardial washout compared to mediastinal washout.
Dosimetry
Data on radiation absorbed dose estimates for MIBG (
123I
or
131I) in human subjects are limited and are based on
publications from the early 1980s [25]. The International
Commission on Radiological Protection (ICRP) publication
53 presents estimates of the biokinetic model based on
these early data [26]. In the subsequent addenda to this
ICRP publication (ICRP publication 80, based on some
assumptions from ICRP publication 60), absorbed dose
estimates for MIBG changed due to new assumptions in
specific absorbed fractions to calculate the S values [27, 28].
Although a comparison between the early study of
Jacobsson et al. [25] and our study reveals significant meth-
odological differences (e.g., correction for attenuation, the
number of time points studied), their effective dose estimates
basedonmeasurementswith
131I-MIBG are of the same order
of magnitude as those presented here. However, the higher
absorbed dose estimate in our study is probably related to
differences in the standard input models and methods used to
calculate estimated absorbed doses (OLINDA/EXM).
Our biodistribution data showed intestinal activity already
in the early images. This is a reflection of the sympathetic
Table 2 Radiation-absorbed estimates (mSv/MBq) for
123I-MIBG
ca
123I-MIBG nca
123I-MIBG
Men Women Men Women
Mean±SD Mean±SD Mean±SD Mean±SD
Adrenals 1.08E-02±1.31E-03 1.34E-02±1.61E-03 1.13E-02±8.91E-04 1.41E-02±1.18E-03
Brain 7.69E-04±9.91E-05 7.98E-04±1.02E-04 8.01E-04±1.04E-04 8.25E-04±1.12E-04
Breasts 3.08E-03±3.18E-04 3.82E-03±3.80E-04 3.29E-03±2.72E-04 4.08E-03±3.42E-04
Gallbladder wall 1.68E-02±2.46E-03 2.08E-02±3.01E-03 1.75E-02±1.62E-03 2.17E-02±2.12E-03
Lower large intestine wall 5.94E-02±8.13E-03 6.51E-02±8.76E-03 5.93E-02±6.91E-03 6.50E-02±7.89E-03
Small intestine 1.04E-02±8.80E-04 1.31E-02±1.10E-03 1.06E-02±7.82E-04 1.34E-02±1.03E-03
Stomach wall 6.88E-03±6.60E-04 9.05E-03±8.73E-04 7.27E-03±6.30E-04 9.55E-03±8.16E-04
Upper large intestine wall 4.76E-02±6.68E-03 5.29E-02±7.39E-03 4.76E-02±5.58E-03 5.30E-02±6.46E-03
Heart wall 2.91E-02±3.93E-03 3.76E-02±5.05E-03 3.48E-02±5.98E-03 4.49E-02±8.15E-03
Kidneys 2.90E-02±6.65E-03 3.26E-02±7.30E-03 3.04E-02±6.73E-03 3.41E-02±7.80E-03
Liver 5.01E-02±1.03E-02 6.49E-02±1.33E-02 5.23E-02±7.47E-03 6.78E-02±1.03E-02
Lungs 2.07E-02±3.44E-03 2.70E-02±4.44E-03 2.13E-02±3.08E-03 2.78E-02±4.24E-03
Muscle 8.60E-03±9.11E-04 1.18E-02±1.29E-03 9.14E-03±8.97E-04 1.25E-02±1.34E-03
Ovaries na 1.58E-02±1.00E-03 na 1.60E-02±1.02E-03
Pancreas 1.03E-02±1.15E-03 1.33E-02±1.52E-03 1.09E-02±8.82E-04 1.40E-02±1.20E-03
Red marrow 5.06E-03±4.22E-04 6.13E-03±5.07E-04 5.30E-03±3.94E-04 6.42E-03±5.06E-04
Osteogenic cells 8.45E-03±8.05E-04 1.07E-02±1.02E-03 8.90E-03±7.82E-04 1.12E-02±1.02E-03
Skin 2.72E-03±2.64E-04 3.31E-03±3.17E-04 2.87E-03±2.52E-04 3.50E-03±3.28E-04
Spleen 1.88E-02±4.85E-03 2.31E-02±5.83E-03 1.93E-02±6.25E-03 2.37E-02±7.96E-03
Testes 5.06E-03±3.01E-04 na 5.19E-03±2.83E-04 na
Thymus 5.67E-03±5.46E-04 6.95E-03±6.80E-04 6.21E-03±5.63E-04 7.57E-03±7.27E-04
Thyroid 3.85E-02±7.92E-03 4.58E-02±9.49E-03 4.76E-02±1.90E-02 5.67E-02±2.43E-02
Urinary bladder wall 8.63E-02±9.99E-03 1.27E-01±1.50E-02 8.32E-02±8.86E-03 1.23E-01±1.42E-02
Uterus na 1.65E-02±5.87E-04 na 1.66E-02±5.02E-04
Total body 8.49E-03±7.21E-04 1.02E-02±8.60E-04 8.95E-03±6.25E-04 1.08E-02±7.51E-04
Effective dose equivalent (mSv/MBq) 2.48E-02±1.47E-03
a 3.14E-02±1.78E-03
c 2.59E-02±1.63E-03 3.28E-02±1.34E-03
Effective dose (mSv/MBq) 2.87E-02±2.49E-03
b 3.53E-02±2.87E-03
d 2.94E-02±1.69E-03 3.60E-02±2.00E-03
na Not applicable
aca male vs nca male p=0.055
bca male vs nca male p=0.181
cca female vs nca female p=0.026
dca female vs nca female p=0.177
Eur J Nucl Med Mol Imaging (2008) 35:798–807 805intestinal activity. Sympathetic nerve fibers enter the intesti-
nal wall along arteries and terminate in the mesenteric and
submucosal plexuses and in the mucosa [19, 20]. It is
important to mention that sympathetic nerve fibers not only
terminate in vessel walls or enteric plexuses to control
vascular tone or secretomotor neurons but also end in the
larger vicinity of blood vessels in the submucosa and
mucosa. With respect to the gut-associated lymphoid tissue,
represented by the appendix and Peyer’s patches, sympa-
thetic noradrenergic nerve fibers innervate both the vascu-
lature and parenchymal fields of lymphocytes [20]. The
OLINDA/EXM software estimates intestinal absorbed dose
only on basis of intra-luminal activity and does not allow
direct calculation of dose from intestinal wall to intestinal
wall. Doses given by the software were manually corrected,
retaining the photon dose contribution but correcting the
electron dose contribution to reflect the appropriate target
mass (details not shown).
There were relatively small differences in radiation-
absorbed dose estimates between ca
123I-MIBG and nca
123I-MIBG. The difference between male and female dose
estimates are related to the OLINDA/EXM input model
based on a 73 kg adult male and 57 kg adult female model.
The calculated radiation-absorbed dose estimates for both ca
123I-MIBG and nca
123I-MIBG remain well within the range
of doses acceptable in clinical nuclear medicine studies.
Based on an averaged (male and female model) effective
dose equivalent of 0.03 mSv/MBq derived from the results
of this study, both patients and human volunteers could be
investigated with amounts of up to 185 MBq, which gives an
average effective dose equivalent of approximately 5.6 mSv.
In a 1988 publication, an average effective dose equivalent
per patient from nuclear medicine procedures of 5 mSv was
reported in Europe [29]. In a more recent publication from
the USA, there is a tendency to a higher averaged effective
dose equivalent per nuclear medicine procedure, up to
10 mSv [30]. With respect to human volunteers, the average
effective dose equivalent fell well within the range of 1 and
10 mSv of category IIb of ICRP publication 62 [31]. This is
considered an acceptable risk for volunteers.
Approximately 35% of injected
123I-MIBG was excreted
by 6 h, with excretion starting within 30 min after injection.
Due to this rapid urinary excretion, frequent voiding is to
be recommended to minimize the absorbed dose, especially
to the urinary bladder wall but also to the gonads and other
urinary bladder surrounding tissues.
Future perspective
Application of the semi-quantitative parameters of myocar-
dial
123I-MIBG uptake for prognostic assessment of
patients with heart failure shows promise. However,
estimates of the hazard ratio among studies differ substan-
tially. This is reflected in the absence of
123I-MIBG in any
of the current guidelines regarding either heart failure or
myocardial scintigraphic imaging [32–36]. To apply uni-
form prognostic threshold values, unequivocal methods for
obtaining semi-quantitative parameters of myocardial
123I-
MIBG uptake have as yet to be established.
It is conceivable that the substantially higher myocardial
uptake with nca
123I-MIBG will lead to a lower variability
and therefore to a better correlation with other (clinical)
parametersofheartfailure.Inlinewiththis,itistobeexpected
that,comparedtoca
123I-MIBG, nca
123I-MIBG may perform
better in the assessment of prognosis. However, this remains
subject for future studies.
Conclusion
No-carrier-added
123I-MIBG yields a higher relative myo-
cardial uptake and is associated with a higher myocardial
retention. The difference between nca
123I-MIBG and ca
123I-MIBG in myocardial uptake did not result in major
differences in estimated absorbed dose. For the assessment
of cardiac sympathetic activity, nca
123I-MIBG is therefore
to be preferred over ca
123I-MIBG.
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